Discovery of a new boron-containing antifungal agent, 5-fluoro-1,3-dihydro-1-hydroxy-2,1- benzoxaborole (AN2690), for the potential treatment of onychomycosis.

Abstract

A structure-activity relationship investigation for a more efficacious therapy to treat onychomycosis, a fungal infection of the toe and fingernails, led to the discovery of a boron-containing small molecule, 5-fluoro-1,3-dihydro-1-hydroxy-2,1-benzoxaborole (AN2690), which is currently in clinical trials for onychomycosis topical treatment.

• Authors: Stephen J Baker, Yong-Kang Zhang, Tsutomu Akama, Agnes Lau, Huchen Zhou, Vincent Hernandez, Weimin Mao, M R K Alley, Virginia Sanders, Jacob J Plattner
• Journal: Journal of medicinal chemistry (J Med Chem) Vol. 49 Issue 15 Pg. 4447-50 (Jul 27 2006) ISSN: 0022-2623 [Print] United States
• PMID: 16854048 (Publication Type: Journal Article)

Chemical References

• Antifungal Agents
• Boron Compounds
• Bridged Bicyclo Compounds, Heterocyclic
• tavaborole

Topics

• Administration, Topical
• Antifungal Agents (chemical synthesis, chemistry, pharmacology)
• Aspergillus fumigatus (drug effects)
• Boron Compounds (chemical synthesis, chemistry, pharmacology)
• Bridged Bicyclo Compounds, Heterocyclic (chemical synthesis, chemistry, pharmacology)
• Candida (drug effects)
• Microbial Sensitivity Tests
• Onychomycosis (drug therapy)
• Structure-Activity Relationship
• Trichophyton (drug effects)